AssetMemo
AssetsMechanismsCompaniesCalendarChartsWatchlistAsk AIMethodology
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
◧AssetMemo
⌕

Evidence-graded drug-asset intelligence
◧AssetMemo
AssetsMechanismsCompaniesReadout CalendarCompare ChartsWatchlist & AlertsAsk AI
Therapeutic areas
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
ReferenceMethodology & RubricUs vs. AI ToolsUK IBD Access GuideAbout the founder

Educational data tool. Evidence graded; securities never are.

BrowseAll assetsAll mechanismsAll companiesReadout calendarReadouts by yearResults by diseaseDelayed readoutsOpen dataCompare share pricesWhat's new
ReferenceMethodology & sourcesUs vs. the AI toolsUK IBD Access GuideAbout the founderAsk the AIReport a problem / suggest a feature

Educational research only, not investment advice. Evidence quality is graded; securities never are. · Terms · Privacy · Logos by Logo.dev

Ask

Opening the console…

1,457 drug developers and their pipelines

Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.

Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.

← browse by therapeutic area

Views

1457 of 1457 companies

CompanyPipelineMost advancedNext readoutMarket capCash & inv.RunwayR&D / yr
Epkin logo
EpkinPrivate
1 asset: 1 Ph 1OKN4395Phase 1 · Non-Small Cell Lung CancerJul 2028OKN4395 · Phase 1————
E
ERIGENPrivate
1 asset: 1 Ph 2KQ-2003Phase 1/2 · Multiple MyelomaWeak signal31 Dec 2027KQ-2003 · Phase 1————
ERX Pharmaceuticals logo
ERX PharmaceuticalsPrivate
1 asset: 1 Ph 2ERX1000Phase 2 · ObesityWeak signalMay 2027ERX1000 · Phase 2————
Esperion Therapeutics logo
Esperion TherapeuticsPrivate
2 assets: 2 approvedApproved assets onlyNone on record—$156MMar 2026~6.2 qtrs$44M
Essen Biotech logo
Essen BiotechPrivate
3 assets: 3 Ph 2CD123/CD33 CARTPhase 1/2 · Acute Myeloid Leukemia28 Dec 2027EB-SELECT Single-Target CAR-NK Cells · Phase 1/2————
Essential Pharma logo
Essential PharmaPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
Eurofarma Laboratorios logo
Eurofarma LaboratoriosPrivate
3 assets: 1 approved, 2 Ph 3EvogliptinPhase 3 · Type 2 DiabetesReliable signal31 Jan 2027Cenobamate · Phase 2————
EVER Neuro Pharma (EVER Pharma) logo
EVER Neuro Pharma (EVER Pharma)Private
1 asset: 1 Ph 2CerebrolysinPhase 2 · Alzheimer's DiseasePartial signalNone on record————
Evopoint Biosciences Inc. logo
Evopoint Biosciences Inc.Private
1 asset: 1 Ph 2ASP546CPhase 1/2 · Non-Small Cell Lung Cancer30 Dec 2026ASP546C · Phase 1/2————
E
EwopharmaPrivate
2 assets: 2 Ph 3SugemalimabPhase 3 · Non-Small Cell Lung CancerReliable signalDec 2029Sugemalimab · Phase 3————
Exciva GmbH logo
Exciva GmbHPrivate
2 assets: 2 Ph 3DeramciclanePhase 2/3 · Alzheimer's DiseaseJan 2029Deramciclane · Phase 2/3————
EXCYTE (Beijing) Pharmaceutical Technology Development Co., Ltd. logo
EXCYTE (Beijing) Pharmaceutical Technology Development Co., Ltd.Private
1 asset: 1 Ph 2YKST02Phase 2 · Multiple MyelomaNone on record————
Ferrer Internacional logo
Ferrer InternacionalPrivate
2 assets: 1 Ph 3, 1 Ph 2Loxapine (Adasuve)Phase 3 · SchizophreniaReliable signalNone on record————
Ferring Pharmaceuticals logo
Ferring PharmaceuticalsPrivate
3 assets: 2 approved, 1 Ph 2olamkiceptPhase 2 · Ulcerative ColitisPartial signalNone on record————
FindCure Biosciences (ZhongShan) Co., Ltd. logo
FindCure Biosciences (ZhongShan) Co., Ltd.Private
1 asset: 1 Ph 1INN805Phase 1 · Non-Small Cell Lung CancerDec 2026INN805 · Phase 1————
F
Flamingo TherapeuticsPrivate
1 asset: 1 Ph 2DanvatirsenPhase 2 · Non-Small Cell Lung CancerNone on record————
Fortis Therapeutics, Inc. logo
Fortis Therapeutics, Inc.Private
1 asset: 1 Ph 1FOR46Phase 1 · Multiple MyelomaWeak signal31 Mar 2028FOR46 · Phase 2————
FORUS Therapeutics Inc. logo
FORUS Therapeutics Inc.Private
1 asset: 1 approvedApproved assets onlyDec 2026Selinexor · Phase 2/3————
F
Fosun Wanbang Pharma GroupPrivate
1 asset: 1 Ph 3RoconkibartPhase 3 · PsoriasisReliable signalNone on record————
Frontier Medicines Corporation logo
Frontier Medicines CorporationPrivate
1 asset: 1 Ph 2FMC-376Phase 1/2 · Non-Small Cell Lung CancerOct 2027FMC-376 · Phase 1/2————
Fujifilm Pharmaceuticals U.S.A., Inc. logo
Fujifilm Pharmaceuticals U.S.A., Inc.Private
1 asset: 1 Ph 2Gemcitabine (FF-10832)Phase 2 · Non-Small Cell Lung CancerMay 2029Gemcitabine (FF-10832) · Phase 2————
FUJIFILM Toyama Chemical logo
FUJIFILM Toyama ChemicalPrivate
1 asset: 1 Ph 3IguratimodPhase 3 · Rheumatoid ArthritisPartial signalNone on record————
F
Future Pak, LLCPrivate
1 asset: 1 approvedApproved assets onlyDec 2026Crofelemer · Phase 2/3————
G2GBio, Inc. logo
G2GBio, Inc.Private
1 asset: 1 Ph 1GB-5001Phase 1 · Alzheimer's DiseaseWeak signalNone on record————
G
G42 HealthcarePrivate
1 asset: 1 Ph 3cadisegliatinPhase 3 · Type 1 DiabetesWeak signalApr 2027cadisegliatin · Phase 3————
G
Gaelan MedicalPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
G
Gebro Pharma GmbHPrivate
1 asset: 1 Ph 3PiclidenosonPhase 3 · PsoriasisPartial signal31 Aug 2027Piclidenoson · Phase 2————
GeneCradle Inc logo
GeneCradle IncPrivate
1 asset: 1 Ph 1GC304Phase 1 · Severe HypertriglyceridemiaDec 2026GC304 · Phase 1————
GeneCraft Inc. logo
GeneCraft Inc.Private
1 asset: 1 Ph 1RX001Phase 1 · Non-Small Cell Lung CancerNone on record————
Genemagic Biosciences Co., Ltd. logo
Genemagic Biosciences Co., Ltd.Private
1 asset: 1 Ph 1GM101Phase 1 · Parkinson's Disease17 Feb 2027GM101 · Phase 1————
Genetix Biotherapeutics Inc. (formerly bluebird bio, Inc.) logo
Genetix Biotherapeutics Inc. (formerly bluebird bio, Inc.)Private
1 asset: 1 approvedApproved assets onlyMay 2027Lovotibeglogene autotemcel (Lyfgenia) · Phase 3————
Gensco Laboratories LLC logo
Gensco Laboratories LLCPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
G
GeropharmPrivate
1 asset: 1 Ph 3EvogliptinPhase 3 · Type 2 DiabetesReliable signalNone on record————
GI Cell, Inc. logo
GI Cell, Inc.Private
1 asset: 1 Ph 2GIC-102Phase 1/2 · Multiple MyelomaWeak signalNone on record————
G
Gilgamesh PharmaPrivate
1 asset: 1 Ph 2BlixeprodilPhase 2 · Major Depressive DisorderWeak signalNone on record————
Glaceum logo
GlaceumPrivate
1 asset: 1 Ph 2VutiglabridinPhase 2 · Parkinson's DiseasePartial signalNone on record————
Gloria Biosciences logo
Gloria BiosciencesPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
GluBio Therapeutics Inc. logo
GluBio Therapeutics Inc.Private
1 asset: 1 Ph 1GLB-001Phase 1 · Acute Myeloid LeukemiaNone on record————
GNT Biotech & Medicals logo
GNT Biotech & MedicalsPrivate
1 asset: 1 Ph 3ChidamidePhase 3 · HR+/HER2- Metastatic Breast CancerReliable signal31 May 2028Chidamide · Phase 3————
GPCR Therapeutics, Inc. logo
GPCR Therapeutics, Inc.Private
1 asset: 1 Ph 2Burixafor (TG-0054)Phase 2 · Multiple MyelomaWeak signalNone on record————
G
Grand Theravac Life Science (Nanjing) Co., Ltd.Private
2 assets: 1 Ph 3, 1 Ph 1TVAX-008Phase 3 · Chronic Hepatitis BNone on record————
Grey Wolf Therapeutics logo
Grey Wolf TherapeuticsPrivate
1 asset: 1 Ph 2GRWD5769Phase 1/2 · Non-Small Cell Lung Cancer30 Apr 2027GRWD5769 · Phase 1/2————
Grit Biotechnology logo
Grit BiotechnologyPrivate
1 asset: 1 Ph 1GT737Phase 1 · Acute Myeloid LeukemiaJun 2030GT737 · Phase 1————
Grünenthal GmbH logo
Grünenthal GmbHPrivate
4 assets: 3 approved, 1 Ph 3rexlemestrocel-LPhase 3 · Heart FailurePartial signalJul 2027rexlemestrocel-L · Phase 3————
Guangdong Raynovent Biotech logo
Guangdong Raynovent BiotechPrivate
1 asset: 1 Ph 3RAY1225Phase 3 · Obesity1 Dec 2026RAY1225 · Phase 3————
Guangzhou Bio-gene Technology Co., Ltd logo
Guangzhou Bio-gene Technology Co., LtdPrivate
1 asset: 1 Ph 2BG1805Phase 1/2 · Acute Myeloid LeukemiaMar 2027BG1805 · Phase 1/2————
Guangzhou Henovcom Bioscience Co. Ltd. logo
Guangzhou Henovcom Bioscience Co. Ltd.Private
1 asset: 1 Ph 1HNC364Phase 1 · Parkinson's DiseaseWeak signal31 Dec 2026HNC364 · Phase 1————
G
Guangzhou JOYO PharmaPrivate
2 assets: 1 Ph 3, 1 Ph 2FudotinibPhase 3 · Non-Small Cell Lung Cancer31 Oct 2027Fudotinib · Phase 3————
Guangzhou Magpie Pharmaceuticals logo
Guangzhou Magpie PharmaceuticalsPrivate
1 asset: 1 Ph 1MN-08Phase 130 Mar 2028MN-08 · Phase 1————
G
Guangzhou Novaken Pharm Co., Ltd.Private
1 asset: 1 Ph 2XJN010Phase 2 · Parkinson's DiseaseNone on record————
GV20 Therapeutics logo
GV20 TherapeuticsPrivate
1 asset: 1 Ph 2GV20-0251Phase 2 · Non-Small Cell Lung Cancer15 Dec 2026GV20-0251 · Phase 1/2————
GW Pharmaceuticals logo
GW PharmaceuticalsPrivate
1 asset: 1 approvedApproved assets only1 Aug 2027Cannabidiol (Epidiolex) · Approved————
Gyala Therapeutics logo
Gyala TherapeuticsPrivate
1 asset: 1 Ph 2CART84Phase 1/2 · Acute Myeloid Leukemia31 May 2029CART84 · Phase 1/2————
Haihe Biopharma logo
Haihe BiopharmaPrivate
1 asset: 1 Ph 3GlumetinibPhase 3 · Non-Small Cell Lung CancerNone on record————
Halia Therapeutics logo
Halia TherapeuticsPrivate
1 asset: 1 Ph 2HT-4253Phase 2 · Alzheimer's DiseaseFeb 2028HT-4253 · Phase 2————
Handa Neuroscience, LLC logo
Handa Neuroscience, LLCPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
Hangzhou Dinovate Biotech logo
Hangzhou Dinovate BiotechPrivate
1 asset: 1 Ph 2DNV001Phase 2 · Atherosclerotic Cardiovascular Disease30 Jun 2027DNV001 · Phase 2————
Hangzhou Highlightll Pharmaceutical logo
Hangzhou Highlightll PharmaceuticalPrivate
4 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1, 1 otherBHV-8000Phase 2/3 · Parkinson's Disease30 Jun 2027HL-300 · Phase 1/2————
Hangzhou Polymed Biopharmaceuticals, Inc. logo
Hangzhou Polymed Biopharmaceuticals, Inc.Private
1 asset: 1 Ph 1HPB-092Phase 1 · Acute Myeloid LeukemiaJun 2027HPB-092 · Phase 1————
Hangzhou Sumgen Biotech Co., Ltd. logo
Hangzhou Sumgen Biotech Co., Ltd.Private
3 assets: 2 Ph 3, 1 Ph 2SanritatugPhase 3 · Multiple MyelomaWeak signal31 Mar 2027Sanritatug · Phase 2————
Hangzhou Weben Pharma Co., Ltd logo
Hangzhou Weben Pharma Co., LtdPrivate
1 asset: 1 Ph 1WBC100Phase 1 · Acute Myeloid LeukemiaDec 2026WBC100 · Phase 1————
H
HC Biopharma Inc.Private
2 assets: 1 Ph 2, 1 Ph 1HC010Phase 2 · Non-Small Cell Lung Cancer30 Dec 2026HC010 · Phase 2————
Hebei Senlang Biotechnology logo
Hebei Senlang BiotechnologyPrivate
2 assets: 1 Ph 2, 1 otherSENL103Phase 1/2 · Multiple MyelomaWeak signal1 Feb 2028SENL103 · Phase 1/2————
Hefei TG ImmunoPharma Co., Ltd. logo
Hefei TG ImmunoPharma Co., Ltd.Private
1 asset: 1 Ph 1TGI-5Phase 1 · Non-Small Cell Lung Cancer31 Oct 2027TGI-5 · Phase 1————
H
HekaBio K.K.Private
1 asset: 1 Ph 2TroculeucelPhase 1/2 · Alzheimer's DiseaseWeak signalMar 2028Troculeucel · Phase 1/2————
HELP Therapeutics logo
HELP TherapeuticsPrivate
1 asset: 1 Ph 3HiCM-188 (allogeneic iPSC-cardiomyocytes)Phase 3 · Heart FailurePartial signal30 Jun 2027HiCM-188 (allogeneic iPSC-cardiomyocytes) · Phase 3————
Henan Genuine Biotech logo
Henan Genuine BiotechPrivate
4 assets: 1 Ph 3, 3 Ph 2AzvudinePhase 3 · HIVPartial signalDec 2026CL-197 · Phase 2————
HiFiBiO Therapeutics logo
HiFiBiO TherapeuticsPrivate
2 assets: 2 Ph 1EmunkitugPhase 1 · Non-Small Cell Lung CancerDec 2026Emunkitug · Phase 1————
Hillhurst Biopharmaceuticals, Inc. logo
Hillhurst Biopharmaceuticals, Inc.Private
1 asset: 1 Ph 2HBI-002Phase 2 · Parkinson's Disease31 Dec 2026HBI-002 · Phase 2————
HMNC Brain Health logo
HMNC Brain HealthPrivate
1 asset: 1 Ph 2NelivaptanPhase 2 · Major Depressive DisorderPartial signalNone on record————
Hong Kong King-Friend Industrial Co., Ltd. logo
Hong Kong King-Friend Industrial Co., Ltd.Private
1 asset: 1 approvedApproved assets onlyNone on record————
Hong Kong WD Pharmaceutical Co., Limited logo
Hong Kong WD Pharmaceutical Co., LimitedPrivate
1 asset: 1 Ph 2Carbidopa/levodopa (WD-1603)Phase 2 · Parkinson's DiseasePartial signalNone on record————
Hrain Biotechnology Co., Ltd. logo
Hrain Biotechnology Co., Ltd.Private
4 assets: 2 Ph 2, 2 Ph 1Hrain anti-BCMA CAR-TPhase 2 · Multiple MyelomaWeak signalNone on record————
Huabo Biopharm Co. logo
Huabo Biopharm Co.Private
2 assets: 2 Ph 3HB0017Phase 3 · PsoriasisPartial signal31 Dec 2026HB0017 · Phase 1————
Huahui Health logo
Huahui HealthPrivate
2 assets: 1 Ph 3, 1 Ph 1Libevitug (HH-003)Phase 3 · Chronic Hepatitis DeltaAug 2027HH160 · Phase 1————
Humanetics Corporation logo
Humanetics CorporationPrivate
1 asset: 1 Ph 2BIO 300Phase 2 · Non-Small Cell Lung CancerWeak signalNone on record————
Hummingbird Bioscience logo
Hummingbird BiosciencePrivate
2 assets: 2 Ph 2NezutatugPhase 1/2 · Non-Small Cell Lung CancerWeak signalJul 2027ENV-501 · Phase 1/2————
HuniLife Biotechnology, Inc. logo
HuniLife Biotechnology, Inc.Private
1 asset: 1 Ph 2HuL001Phase 1/2 · Multiple Myeloma30 Nov 2027HuL001 · Phase 1/2————
HUYABIO International, LLC. logo
HUYABIO International, LLC.Private
5 assets: 2 Ph 3, 1 Ph 2, 2 Ph 1ChidamidePhase 3 · HR+/HER2- Metastatic Breast CancerReliable signal30 Dec 2026GH21 · Phase 2————
Iambic Therapeutics, Inc logo
Iambic Therapeutics, IncPrivate
1 asset: 1 Ph 2IAM1363Phase 1/2 · Non-Small Cell Lung CancerOct 2028IAM1363 · Phase 1/2————
IASO Biotherapeutics logo
IASO BiotherapeuticsPrivate
2 assets: 1 Ph 3, 1 Ph 1Equecabtagene autoleucelPhase 3 · Multiple MyelomaNone on record————
iCamuno Biotherapeutics Ltd. logo
iCamuno Biotherapeutics Ltd.Private
2 assets: 2 Ph 1ALC01Phase 1 · Parkinson's Disease15 Dec 2027ALC01 · Phase 1————
iCell Gene Therapeutics logo
iCell Gene TherapeuticsPrivate
4 assets: 1 Ph 2, 3 Ph 1ICG318Phase 2 · Systemic Lupus Erythematosus31 Dec 2027ICG318 · Phase 1————
I
Ichnos SciencesPrivate
1 asset: 1 Ph 2ABBV-2001Phase 1/2 · Multiple MyelomaJul 2027ABBV-2001 · Phase 1————
I
IdB HoldingPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
IDP Discovery Pharma S.L. (IDP Pharma) logo
IDP Discovery Pharma S.L. (IDP Pharma)Private
1 asset: 1 Ph 2IDP-121Phase 1/2 · Multiple Myeloma30 Jul 2028IDP-121 · Phase 1/2————
iLeukon Therapeutics, Inc. logo
iLeukon Therapeutics, Inc.Private
1 asset: 1 Ph 2ILKN421HPhase 2 · Non-Small Cell Lung CancerJun 2029ILKN421H · Phase 2————
Imbioray (Hangzhou) Biomedicine Co., Ltd. logo
Imbioray (Hangzhou) Biomedicine Co., Ltd.Private
1 asset: 1 Ph 1IBR733Phase 1 · Acute Myeloid Leukemia1 Jul 2027IBR733 · Phase 1————
Imbria Pharmaceuticals logo
Imbria PharmaceuticalsPrivate
1 asset: 1 Ph 2NinerafaxstatPhase 2 · Heart FailureWeak signalDec 2026Ninerafaxstat · Phase 2————
Immedica Pharma AB logo
Immedica Pharma ABPrivate
1 asset: 1 approvedApproved assets onlyDec 2029Ganaxolone · Phase 3————
Immune-Onc Therapeutics logo
Immune-Onc TherapeuticsPrivate
1 asset: 1 Ph 1IO-202Phase 1 · Acute Myeloid LeukemiaWeak signalNone on record————
Immunitas Therapeutics logo
Immunitas TherapeuticsPrivate
1 asset: 1 Ph 2RezorstobartPhase 1/2 · Non-Small Cell Lung CancerWeak signalNone on record————
Immuno Cure BioTech logo
Immuno Cure BioTechPrivate
1 asset: 1 Ph 1AV000103A (ICVAX)Phase 1 · HIVWeak signalNone on record————
Immunobrain Checkpoint logo
Immunobrain CheckpointPrivate
1 asset: 1 Ph 1IBC-Ab002Phase 1 · Alzheimer's DiseasePartial signalNone on record————
I
Immunocell Therapeutics, Inc.Private
1 asset: 1 Ph 1KB-GDT-01Phase 1 · Non-Small Cell Lung CancerNone on record————
Immunophotonics, Inc. logo
Immunophotonics, Inc.Private
1 asset: 1 Ph 3N-dihydrogalactochitosanPhase 2/3 · Colorectal CancerDec 2033N-dihydrogalactochitosan · Phase 2/3————
Immunwork logo
ImmunworkPrivate
1 asset: 1 Ph 2TE-8105Phase 2 · ObesityWeak signalFeb 2028TE-8105 · Phase 2————
ImmVira Pharma logo
ImmVira PharmaPrivate
1 asset: 1 Ph 2T3011Phase 1/2 · Non-Small Cell Lung CancerWeak signal31 Dec 2028T3011 · Phase 2————
I
Imperial College LondonPrivate
1 asset: 1 Ph 2RAD101Phase 2 · Brain MetastasesNone on record————
Incendia Therapeutics logo
Incendia TherapeuticsPrivate
1 asset: 1 Ph 1EnsavatatugPhase 1 · Non-Small Cell Lung CancerNone on record————

Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.

Page123456789101112131415